Angeion Corporation to Exhibit at 2009 European Respiratory Society Congress in Vienna, Austria

Company to Preview New MedGraphics CPX Express

SAINT PAUL, Minn. (Sept. 3, 2009) — Angeion Corporation (NASDAQ: ANGN) today announced that it will exhibit at the 2009 European Respiratory Society (ERS) Congress in Vienna, Austria, Sept. 12-16.

At booth G30 in hall B, Angeion will preview its all-new MedGraphics CPX Express. This compact, easy-to-use system provides breath-by-breath cardiorespiratory and functional capacity testing. It is designed to meet the needs of all exercise specialists including those in the fields of cardiology and sports medicine.  A formal product launch for the CPX Express is scheduled for October 2009.

“We are excited to preview the MedGraphics CPX Express at this year’s ERS Congress,” said Rodney A. Young, Angeion’s President and Chief Executive Officer. “This is pulmonary medicine’s largest international gathering, and the perfect platform to introduce and showcase our cardiopulmonary diagnostic, health management and fitness systems and products with an international community of industry leaders and experts.” 

Also at the ERS Congress, Angeion will display its broad line of MedGraphics products including the CCM Express®.  Launched in early 2009 by the company, the CCM Express can be used in clinical care, bariatric surgery, diabetes management and oncology care, as well as other nutrition applications to provide accurate and reliable metabolic measurement. 

The ERS Congress, the largest gathering in pulmonary medicine worldwide, provides a unique forum where approximately 18,000 scientists and medical professionals from around the world have the opportunity to meet and exchange ideas and information in the field of respiratory medicine.For more information on the 2009 ERS Congress, visit:
http://dev.ersnet.org/725-welcome-address.htm

About Angeion Corporation
Founded in 1986, Angeion Corporation acquired Medical Graphics Corporation in December 1999. Medical Graphics develops, manufactures and markets non-invasive cardiorespiratory diagnostic systems that are sold under the MedGraphics (www.medgraphics.com) and New Leaf (www.newleaffitness.com) brand and trade names. These cardiorespiratory diagnostic systems have a wide range of applications in healthcare as well as health and fitness. The Company’s products are sold internationally through distributors and in the United States through a direct sales force that targets heart and lung specialists located in hospitals, university-based medical centers, medical clinics and physicians’ offices, pharmaceutical companies, medical device manufacturers, clinical research organizations, health and fitness clubs, personal training studios, and other exercise facilities. For more information about Angeion, visit www.angeion.com.

The discussion above contains forward-looking statements about Angeion’s future financial results and business prospects that by their nature involve substantial risks and uncertainties.  You can identify these statements by the use of words such as “anticipate,” “believe,” “estimate,” “expect,” “project,” “intend,” “plan,” “will,” “target,” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects.  Our actual results may differ materially depending on a variety of factors including: (1) national and worldwide economic and capital market conditions; (2) continuing cost-containment efforts in our hospital, clinics, and office market; (3) our ability to successfully operate our business, including our ability to develop, improve, and update our cardiorespiratory diagnostic products and successfully sell these products under the MedGraphics and New Leaf brand names into existing and new markets; (4) our ability to maintain our cost structure at a level that is appropriate to our near to mid-term revenue expectations and that will enable us to increase revenues and profitability as opportunities develop; (5) our ability to achieve constant margins for our products and consistent and predictable operating expenses in light of variable revenues from our clinical research customers; (6) our ability to effectively manufacture and ship products in required quantities to meet customer demands; (7) our ability to expand our international revenue through our distribution partners and our Milan, Italy representative branch office; (8) our ability to successfully defend ourselves from product liability claims related to our cardiorespiratory diagnostic products and claims associated with our prior cardiac stimulation products; (9) our ability to defend our intellectual property; (10) our ability to develop and maintain an effective system of internal controls and procedures and disclosure controls and procedures; and (11) our dependence on third-party vendors.  Additional information with respect to the risks and uncertainties faced by the Company may be found in, and the above discussion is qualified in its entirety by, the other risk factors that are described from time to time in the Company’s Securities and Exchange Commission reports, including the Annual Report on Form 10-K for the year ended October 31, 2008.

Contact:           William J. Kullback, SVP & Chief Financial Officer, (651) 766-3492